Search
ROG.VX: APHINITY’s fine line: 5-year data raises more concerns with Perjeta
Five-year data raises more concerns over Perjeta’s scope in early stage breast cancer trial APHINITY
Our updated analysis following the San Antonio breast cancer symposium last week reveals further concerns that could lead to Perjeta either struggling in the APHNITY trial in early-stage breast or being used in a much restricted population than what the market is hoping for...
